Skip to main content

Advertisement

SpringerLink
Log in

LINC02532 by Mediating miR-541-3p/HMGA1 Axis Exerts a Tumor Promoter in Breast cancer

  • Original Paper
  • Published:
Molecular Biotechnology Aims and scope Submit manuscript

Abstract

The newly discovered LINC02532 is abnormally expressed in a variety of cancers and promotes cancer progression. The research proposed to discover the biological and molecular mechanisms of LINC02532 in breast cancer (BCa). In the resected BCa tissue samples and adjacent normal tissues, LINC02532, miR-541-3p, and High Mobility Group A1 (HMGA1) levels were determined. Cell function experiments were carried out on the premise of cell transfection with relevant plasmids. Based on that, the influence of LINC02532, miR-541-3p, and HMGA1 on MCF-7 cell activities (proliferation, migration, invasion, cell cycle, and apoptosis) was determined, as well as on EMT. Additionally, animal experiments were allowed to support cell experimental conclusions on LINC02532. Finally, the mechanistic network of LINC02532, miR-541-3p, and HMGA1 was identified. It was BCa tissues highly expressing LINC02532 and HMGA1, while lowly expressing miR-541-3p. Functionally, LINC02532 depletion repressed the activities and EMT process of MCF-7 cells. Silencing LINC02532 delayed tumor growth in mice. In terms of mechanism, LINC02532 mainly existed in the cytoplasm and could mediate HMGA1 expression by absorbing miR-541-3p. The findings offer new insights into the molecular mechanisms of LINC02532 in BCa and, more importantly, new strategies for the clinical treatment of BCa.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

Data Availability

Data is available from the corresponding author on request.

References

  1. Bray, F., et al. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. C Ca: A Cancer Journal for Clinicians, 68(6), 394–424.

    Google Scholar 

  2. Dabi, Y., et al. (2022). Overview of non-coding RNAs in breast cancers. Transl Oncol, 25, 101512.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Siegel, R. L., Miller, K. D., & Jemal, A. (2020). Cancer statistics, 2020. C Ca: A Cancer Journal for Clinicians, 70(1), 7–30.

    Google Scholar 

  4. Gibb, E. A., Brown, C. J., & Lam, W. L. (2011). The functional role of long non-coding RNA in human carcinomas. Molecular Cancer, 10, 38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Yao, R. W., Wang, Y., & Chen, L. L. (2019). Cellular functions of long noncoding RNAs. Nature Cell Biology, 21(5), 542–551.

    Article  CAS  PubMed  Google Scholar 

  6. Kondo, Y., Shinjo, K., & Katsushima, K. (2017). Long non-coding RNAs as an epigenetic regulator in human cancers. Cancer Science, 108(10), 1927–1933.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Hanniford, D., et al. (2020). Epigenetic silencing of CDR1as drives IGF2BP3-Mediated Melanoma Invasion and Metastasis. Cancer Cell, 37(1), 55–70e15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Huarte, M. (2015). The emerging role of lncRNAs in cancer. Nature Medicine, 21(11), 1253–1261.

    Article  CAS  PubMed  Google Scholar 

  9. Huo, X., et al. (2017). Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: Implications for tumorigenesis, Disease progression, and Liver cancer stem cells. Molecular Cancer, 16(1), 165.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Flores-Huerta, N. (2021). LncRNAs and microRNAs as essential regulators of stemness in Breast Cancer stem cells. Biomolecules, 11(3).

  11. Yang, Y. X., et al. (2018). Long non-coding RNA p10247, high expressed in Breast cancer (lncRNA-BCHE), is correlated with Metastasis. Clinical & Experimental Metastasis, 35(3), 109–121.

    Article  CAS  Google Scholar 

  12. Gupta, R. A., et al. (2010). Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer Metastasis. Nature, 464(7291), 1071–1076.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lakshmi, S., Hughes, T. A., & Priya, S. (2021). Exosomes and exosomal RNAs in Breast cancer: A status update. European Journal of Cancer, 144, 252–268.

    Article  CAS  PubMed  Google Scholar 

  14. Bliss, S. A., et al. (2016). Mesenchymal stem cell-derived Exosomes Stimulate Cycling quiescence and early Breast Cancer Dormancy in Bone Marrow. Cancer Research, 76(19), 5832–5844.

    Article  CAS  PubMed  Google Scholar 

  15. Zhang, C., et al. (2019). Novel long non-coding RNA LINC02532 promotes gastric cancer cell proliferation, migration, and invasion in vitro. World Journal of Gastrointestinal Oncology, 11(2), 91–101.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Zhou, X. (2021). LINC02532 contributes to Radiosensitivity in Clear Cell Renal Cell Carcinoma through the miR-654-5p/YY1 Axis. Molecules, 26(22).

  17. Chen, D., et al. (2018). MicroRNA-129-5p regulates glycolysis and cell proliferation by targeting the glucose transporter SLC2A3 in gastric Cancer cells. Frontiers in Pharmacology, 9, 502.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Li, J. (2021). MiR-490-5p Restrains Progression of Gastric cancer through DTL Repression Gastroenterol Res Pract, 2021: p. 2894117.

  19. Wu, D., et al. (2021). STAT3-induced HLA-F-AS1 promotes cell proliferation and stemness characteristics in triple negative Breast cancer cells by upregulating TRABD. Bioorganic Chemistry, 109, 104722.

    Article  CAS  PubMed  Google Scholar 

  20. Xu, Q., et al. (2020). CircIL4R facilitates the tumorigenesis and inhibits ferroptosis in hepatocellular carcinoma by regulating the miR-541-3p/GPX4 axis. Cell Biology International, 44(11), 2344–2356.

    Article  CAS  PubMed  Google Scholar 

  21. Long, B., et al. (2018). Long noncoding RNA LOXL1-AS1 regulates Prostate cancer cell proliferation and cell cycle progression through mir-541-3p and CCND1. Biochemical and Biophysical Research Communications, 505(2), 561–568.

    Article  CAS  PubMed  Google Scholar 

  22. He, Z., et al. (2021). Mir-541-3p enhances the radiosensitivity of Prostate cancer cells by inhibiting HSP27 expression and downregulating beta-catenin. Cell Death Discov, 7(1), 18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Sgarra, R., et al. (2018). High mobility Group A (HMGA) proteins: Molecular instigators of Breast cancer onset and progression. Biochimica Et Biophysica Acta - Reviews on Cancer, 1869(2), 216–229.

    Article  CAS  PubMed  Google Scholar 

  24. Reeves, R. (2010). Nuclear functions of the HMG proteins. Biochimica Et Biophysica Acta, 1799(1–2), 3–14.

    Article  CAS  PubMed  Google Scholar 

  25. Sgarra, R., et al. (2004). Nuclear phosphoproteins HMGA and their relationship with chromatin structure and cancer. Febs Letters, 574(1–3), 1–8.

    Article  CAS  PubMed  Google Scholar 

  26. Pegoraro, S., et al. (2013). HMGA1 promotes metastatic processes in basal-like Breast cancer regulating EMT and stemness. Oncotarget, 4(8), 1293–1308.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Shah, S. N., et al. (2013). HMGA1: A master regulator of Tumor progression in triple-negative Breast cancer cells. PLoS One, 8(5), e63419.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Pegoraro, S., et al. (2015). A novel HMGA1-CCNE2-YAP axis regulates Breast cancer aggressiveness. Oncotarget, 6(22), 19087–19101.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Dowsett, M., et al. (2011). Assessment of Ki67 in Breast cancer: Recommendations from the International Ki67 in Breast Cancer working group. Journal of the National Cancer Institute, 103(22), 1656–1664.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Zabaglo, L., et al. (2010). Comparative validation of the SP6 antibody to Ki67 in Breast cancer. Journal of Clinical Pathology, 63(9), 800–804.

    Article  PubMed  Google Scholar 

  31. Cuzick, J., et al. (2011). Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the genomic health recurrence score in early Breast cancer. Journal of Clinical Oncology, 29(32), 4273–4278.

    Article  PubMed  Google Scholar 

  32. Bartha, A., & Gyorffy, B. (2021). TNMplot.com: A web Tool for the comparison of Gene expression in normal, Tumor and metastatic tissues. International Journal of Molecular Sciences, 22(5).

  33. Zhou, X. (Nov. 2021). LINC02532 Contributes to Radiosensitivity in Clear Cell Renal Cell Carcinoma through the miR-654-5p/YY1 Axis. Molecules (Basel, Switzerland) vol. 26,22 7040. 22.

  34. Wu, Z., et al. (2020). Long noncoding RNA LINC00963 promotes Breast cancer progression by functioning as a molecular sponge for microRNA-625 and thereby upregulating HMGA1. Cell Cycle, 19(5), 610–624.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Cech, T. R., & Steitz, J. A. (2014). The noncoding RNA revolution-trashing old rules to forge new ones. Cell, 157(1), 77–94.

    Article  CAS  PubMed  Google Scholar 

  36. Huang, Q. Y. (2019). Long non-coding RNA: Dual effects on Breast Cancer Metastasis and clinical applications. Cancers (Basel), 11(11).

  37. Han, C., et al. (2019). CCAT1 promotes triple-negative Breast cancer progression by suppressing miR-218/ZFX signaling. Aging (Albany NY), 11(14), 4858–4875.

    Article  CAS  PubMed  Google Scholar 

  38. Tu, Z., et al. (2019). Microenvironmental Regulation of Long Noncoding RNA LINC01133 promotes Cancer Stem Cell-Like phenotypic traits in Triple-negative breast cancers. Stem Cells, 37(10), 1281–1292.

    Article  CAS  PubMed  Google Scholar 

  39. Vidovic, D., et al. (2020). ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells. Cell Death and Differentiation, 27(1), 363–378.

    Article  CAS  PubMed  Google Scholar 

  40. Kong, X., et al. (2019). LncRNA-CDC6 promotes Breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA-215. Journal of Cellular Physiology, 234(6), 9105–9117.

    Article  CAS  PubMed  Google Scholar 

  41. Ye, G., et al. (2022). circ_0041732 promotes Breast Cancer Progression. Molecular Cancer Research, 20(10), 1561–1573.

    Article  CAS  PubMed  Google Scholar 

  42. Hu, C. Y., et al. (2021). Long non-coding RNA NORAD promotes the Prostate cancer cell extracellular vesicle release via microRNA-541-3p-regulated PKM2 to induce bone Metastasis of Prostate cancer. Journal of Experimental & Clinical Cancer Research : Cr, 40(1), 98.

    Article  CAS  PubMed Central  Google Scholar 

  43. Xia, Y. H., et al. (2019). Role of miR-541-3p/TMPRSS4 in the Metastasis and EMT of hepatocellular carcinoma. European Review for Medical and Pharmacological Sciences, 23(24), 10721–10728.

    PubMed  Google Scholar 

  44. Lu, Y. J., et al. (2016). MiR-541-3p reverses cancer progression by directly targeting TGIF2 in non-small cell Lung cancer. Tumour Biology, 37(9), 12685–12695.

    Article  CAS  PubMed  Google Scholar 

  45. Leivonen, S. K., et al. (2014). High-throughput screens identify microRNAs essential for HER2 positive Breast cancer cell growth. Molecular Oncology, 8(1), 93–104.

    Article  CAS  PubMed  Google Scholar 

  46. Zanin, R., et al. (2019). HMGA1 promotes Breast cancer angiogenesis supporting the stability, nuclear localization and transcriptional activity of FOXM1. Journal of Experimental & Clinical Cancer Research : Cr, 38(1), 313.

    Article  PubMed Central  Google Scholar 

  47. Wang, L., et al. (2022). High mobility Group A1 (HMGA1): Structure, biological function, and therapeutic potential. International Journal of Biological Sciences, 18(11), 4414–4431.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Penzo, C. (2019). HMGA1 modulates gene transcription sustaining a Tumor Signalling pathway acting on the Epigenetic Status of Triple-negative Breast Cancer cells. Cancers (Basel), 11(8).

  49. Mendez, O. (2019). Clinical implications of Extracellular HMGA1 in Breast Cancer. International Journal of Molecular Sciences, 20(23).

  50. Treff, N. R., et al. (2004). High-mobility group A1a protein regulates Ras/ERK signaling in MCF-7 human Breast cancer cells. Oncogene, 23(3), 777–785.

    Article  CAS  PubMed  Google Scholar 

  51. Mansoori, B., et al. (2021). The synergy between mir-486-5p and tamoxifen causes profound cell death of tamoxifen-resistant Breast cancer cells. Biomedicine & Pharmacotherapy, 141, 111925.

    Article  CAS  Google Scholar 

  52. Peluso, S. (2010). and Gennaro C. High-Mobility Group A (HMGA) Proteins and Breast Cancer Breast care (Basel, Switzerland) vol. 5,2 : 81–85.

Download references

Acknowledgements

Not applicable.

Funding

1. Shandong Provincial Natural Foundation (NO. ZR2020MH198). 2. Wu Jieping Medical Foundation Clinical Research Special Funding Fund (320.6750.2021-10-43).

Author information

Authors and Affiliations

  1. Department of Geriatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan City, 250021, Shandong Province, China

    ChunMing Zhao

  2. Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324, Jingwu Road, Jinan City, 250021, Shandong Province, China

    Xiao Li, XueQiang Pan & Rui Jiang

  3. Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan City, 250021, Shandong Province, China

    JiaWen Xu

  4. Department of Thyroid and Breast Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, No.324, Jingwu Road, Jinan City, 250021, Shandong Province, China

    YuYang Li

Authors
  1. ChunMing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. XueQiang Pan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. JiaWen Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rui Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. YuYang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Rui Jiang or YuYang Li.

Ethics declarations

Conflict of interests

Authors declared no conflict of interest.

Ethical Approval

All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All subjects was approved by Shandong Provincial Hospital Affiliated to Shandong First Medical University. And The animal experiment research protocol was approved by the Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong First Medical University and performed in accordance with the “Guidelines for the care and use of experimental animals.”

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

12033_2023_995_MOESM1_ESM.tif

Supplementary Material 1: Fig. 1 Upregulation of LINC02532 promotes proliferation, migration, and invasion of MDA-MB-231 cells, and inhibits cell apoptosis pcDNA3.1-LINC02532 was transfected into MDA-MB-231 cells. RT-qPCR detection of the transfection of pcDNA3.1-LINC02532 (A), analysis results of proliferation (B-C), migration and invasion (D), apoptosis rate (E), and cell cycle (F). Data were expressed as mean ± SD, * P < 0.05

12033_2023_995_MOESM2_ESM.tif

Supplementary Material 2: Fig. 2 LINC02532 promotes proliferation, migration, and invasion and inhibits apoptosis of MDA-MB-231 cells by regulating miR-654-5p. si-LINC02532-1 and miR-654-5p inhibitor were co-transfected into MDA-MB-231 cells, RT-qPCR detection of the transfection of si-LINC02532-1 and miR-654-5p inhibitor (A), analysis results of proliferation (B-C), migration and invasion (D), apoptosis rate (E) and cell cycle (F). Data were expressed as mean ± SD, * P < 0.05

Supplementary Material 3

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhao, C., Li, X., Pan, X. et al. LINC02532 by Mediating miR-541-3p/HMGA1 Axis Exerts a Tumor Promoter in Breast cancer. Mol Biotechnol (2023). https://doi.org/10.1007/s12033-023-00995-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12033-023-00995-6

Keywords

Search

Navigation